Publications by authors named "A Y Rusanov"
Macrolactin A (McA) is a secondary metabolite produced by Bacillus species. It has been known for its antimicrobial properties since the late 1980s, although the exact mechanism of its antibacterial activity remains unknown. In this study, we have found that McA is an inhibitor of protein synthesis in bacteria.
View Article and Find Full Text PDFA thorough study of Clear Cell Renal Cell Carcinoma (ccRCC) shows that combining tyrosine kinase inhibitors (TKI) with immune checkpoint inhibitors (ICI) shows promising results in addressing the tumor-promoting influences of abnormal immunological and molecular biomarkers in metastatic Clear Cell Renal Cell Carcinoma (ccRCC). These abnormal biomarkers enhance drug resistance, support tumor growth, and trigger cancer-related genes. Ongoing clinical trials are testing new treatment options that appear more effective than earlier ones.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the neuroprotective effects of conditioned medium (CM) from mesenchymal stem cells (MSCs) that have been activated or pretreated to enhance their therapeutic properties in the context of Alzheimer's disease (AD).
- Results show that CM from activated MSCs has stronger anti-inflammatory effects and improves neuron cell viability under oxidative stress, potentially by increasing the production of growth factors.
- The research highlights the mechanism behind these effects, including the modulation of microglial activity and the activation of the Nrf2/ARE pathway in neuron-like cells.
Keratins 6, 16, and 17 occupy unique positions within the keratin family. These proteins are not commonly found in the healthy, intact epidermis, but their expression increases in response to damage, inflammation, and hereditary skin conditions, as well as cancerous cell transformations and tumor growth. As a result, there is an active investigation into the potential use of these proteins as biomarkers for different pathologies.
View Article and Find Full Text PDFCombining new therapeutics with all--retinoic acid (ATRA) could improve the efficiency of acute myeloid leukemia (AML) treatment. Modeling the process of ATRA-induced differentiation based on the transcriptomic profile of leukemic cells resulted in the identification of key targets that can be used to increase the therapeutic effect of ATRA. The genome-scale transcriptome analysis revealed the early molecular response to the ATRA treatment of HL-60 cells.
View Article and Find Full Text PDF